Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04730258 · ClinicalTrials.gov registry record · Phase 1

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Treadwell Therapeutics.

Active
Registry status
Phase 1
Development phase
72
Enrollment target
9
Study locations

NCT04730258 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Treadwell Therapeutics. The registered enrollment target is 72 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04730258, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Treadwell Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia AML MDS CMML

Interventions

  • DRUG Azacitidine
  • DRUG CFI-400945

Study Locations (9)

California

  • City of Hope - Duarte
  • University of California Davis Comprehensive Cancer Center - Sacramento

Kentucky

  • Norton Cancer Institute - Saint Matthews - Louisville

New York

  • New York Presbyterian Weill Cornell Medical Center - New York

Ohio

  • The Ohio State University Comprehensive Cancer Center - Columbus

Texas

  • The University of Texas MD Anderson Cancer Centre - Houston

Alberta

  • University of Alberta - Edmonton

Ontario

  • Princess Margaret Cancer Center - Toronto

Other

  • Queen Mary Hospital - Hong Kong

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2021-04-16
Est. Completion 2026-01
Phase Phase 1

Sponsor

Treadwell Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04730258

The ClinicalTrials.gov registry entry for NCT04730258 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The listed sponsor is Treadwell Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.

NCT04730258 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Kentucky, New York.

Frequently Asked Questions

What is clinical trial NCT04730258 about?

NCT04730258 is a clinical study titled "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML". The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

What is the current status of trial NCT04730258?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-04-16. Estimated completion is 2026-01.

What conditions does trial NCT04730258 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS.

What interventions are being tested in trial NCT04730258?

The interventions under investigation include: Azacitidine (DRUG), CFI-400945 (DRUG).

Who is sponsoring clinical trial NCT04730258?

This trial is sponsored by Treadwell Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04730258 being conducted?

This trial has 9 study locations across California, Kentucky, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.